Researchers in South Korea have developed a microfluidic chip that recreates a patient’s own glioblastoma tumor cells along with the surrounding blood vessel environment. The device, described as a “blood–brain tumor barrier chip,” can predict how an individual patient will respond to specific anticancer drugs before treatment begins.
Key takeaways
- The chip models both the tumor and the peritumoral vascular barrier, which often blocks drugs from reaching the brain.
- It uses patient-derived cells, making predictions personalized rather than based on average responses.
- Early tests showed that the chip can distinguish between effective and ineffective treatments for different patients.
- The approach could reduce trial-and-error prescribing for glioblastoma, a notoriously hard-to-treat brain cancer.
Why glioblastoma is so difficult to treat
Glioblastoma is the most aggressive form of brain cancer, with a median survival of around 15 months. One major obstacle is the blood-brain barrier, a protective layer of cells that normally keeps toxins out of the brain but also blocks many chemotherapy drugs. Even when drugs do cross the barrier, the tumor itself can vary widely between patients, meaning a treatment that works for one person may fail in another.
According to the original report from Medical Xpress, the same anticancer drug can produce different effects in different patients with the same type of brain tumor. This variability makes it hard for doctors to choose the right drug without trying it first.
How the chip works
The chip is built using microfluidic technology, which involves tiny channels that guide fluids and cells. The research team, based in South Korea, took cells from a patient’s glioblastoma tumor and also created a model of the blood vessels that surround the tumor. They placed these together on the chip to recreate the natural environment.
Once the chip is set up, the researchers can introduce different anticancer drugs and observe how well they cross the vascular barrier and kill the tumor cells. Because the cells come from a specific patient, the results are tailored to that individual.
Potential benefits for personalized cancer care
If validated in larger studies, this chip could help oncologists choose the most effective drug for each patient before starting treatment. That would spare patients from side effects of ineffective drugs and could speed up the search for a working therapy. The chip might also be used to test new drug combinations or to study how tumors develop resistance over time.
The researchers note that the chip is still in the early stages and needs further testing before it can be used in clinics. However, it represents a step toward more precise, patient-specific medicine for brain cancer.
Frequently Asked Questions
What is a blood–brain tumor barrier chip?
It is a small laboratory device that contains living cells from a patient’s glioblastoma tumor and the blood vessels that surround it. The chip recreates the barrier that drugs must cross to reach the tumor, allowing researchers to test how well different medicines work for that specific patient.
How is this different from standard drug sensitivity tests?
Standard tests often grow tumor cells in a dish without the blood-brain barrier. This chip includes both the tumor and the vascular barrier, which is a major reason many drugs fail in the brain. By modeling that barrier, the chip gives a more realistic picture of how a drug will perform inside the body.
When might this chip be available for patients?
The chip is currently a research tool. More studies are needed to confirm that its predictions match real patient outcomes. If those studies are successful, clinical use could be several years away. The research team is working to refine the technology and test it with larger groups of patients.
This is an original report by Vital Signs Today, informed by reporting from Medical Xpress. Read the original source.
This article is for information only and is not medical advice. See our Medical Disclaimer.
